prikaz prve stranice dokumenta Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use
Rad nije dostupan
Znanstveni rad - Izvorni znanstveni rad
Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use
Journal of Psychopharmacology, / (2024); 2698811241237868. https://doi.org/10.1177/02698811241237868

Papić, Ivan; Bistrović, Petra; Krečak, Ivan; Ortner Hadžiabdić, Maja; Lucijanić, Marko

Citirajte ovaj rad

Papić, I., Bistrović, P., Krečak, I., Ortner Hadžiabdić, M. i Lucijanić, M. (2024). Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use. Journal of Psychopharmacology, /.. doi: 10.1177/02698811241237868

Papić, Ivan, et al. "Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use." Journal of Psychopharmacology, vol. /, 2024. https://doi.org/10.1177/02698811241237868

Papić, Ivan, Petra Bistrović, Ivan Krečak, Maja Ortner Hadžiabdić i Marko Lucijanić. "Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use." Journal of Psychopharmacology / (2024). https://doi.org/10.1177/02698811241237868

Papić, I., et al. (2024) 'Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use', Journal of Psychopharmacology, /. doi: 10.1177/02698811241237868

Papić I, Bistrović P, Krečak I, Ortner Hadžiabdić M, Lucijanić M. Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use. Journal of Psychopharmacology [Internet]. 13.03.2024. [pristupljeno 13.07.2024.];/. doi: 10.1177/02698811241237868

I. Papić, P. Bistrović, I. Krečak, M. Ortner Hadžiabdić i M. Lucijanić, "Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use", Journal of Psychopharmacology, vol. /, Ožujak 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:698082. [Citirano: 13.07.2024.]

Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.